Short answer
PROTHENA CORP PUBLIC LTD CO (PRTA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Prothena announced third-quarter 2026 financial results for the period ended September 30, 2026.
PROTHENA CORP PUBLIC LTD CO 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Prothena announced third-quarter 2026 financial results for the period ended September 30, 2026
- Full operating results and management commentary are in Exhibit 99.1, the company’s November 5, 2026 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss $16.5M, or $0.32 per share, improved from $36.5M and $0.68 in Q3 2025
- Nine-month revenue $52.7M, including a $50.0M Novo milestone tied to coramitug’s Phase 3 trial
- Cash, equivalents and restricted cash $272.2M, with no debt and expected 2026 cash burn of $18M to $23M
- Coramitug hsCRP decreased ~8% versus ~33% increase for placebo, supporting ATTR-CM efficacy ahead of 2029 Phase 3 completion
- Share repurchases reached 2,745,380 shares and $26.6M through nine months under the $100.0M authorization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PROTHENA CORP PUBLIC LTD CO 8-K filings
Get the next PRTA 8-K as it lands
Follow PRTA for push alerts, or ask the research agent what this filing means.